Completed PHASE1 INTERVENTIONAL 2-arm NCT01182077

A Study to Assess Drug Interaction of ASP015K and Midazolam

A Phase 1, Open Label, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP015K and Midazolam After Separate and Concomitant Administration to Healthy Adult Subjects

Sponsor: Astellas Pharma Inc

Conditions Healthy Pharmacokinetics of ASP015K and Midazolam

Interventions ASP015K Midazolam

Updated 5 times since 2017 Last updated: Aug 11, 2010 Started: Jun 30, 2010 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01182077, this PHASE1 trial focuses on Healthy and Pharmacokinetics of ASP015K and Midazolam and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2017 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States